

# Scientific Program

Monday 30 October 2017

|             |   |  |
|-------------|---|--|
| 07:00-17:00 | <b>Registration desk open</b><br>Level 5 foyer, The Pharmacy Australia Centre of Excellence (PACE)  |  |
| 08:30-08:45 | <b>Conference opening</b>   |  |
|             | <b>Room:</b> PACE Auditorium  |  |
|             | <b>Welcome ceremony</b><br>Jesper Hallas, President, International Society for Pharmacoepidemiology; University of Southern Denmark, Denmark<br>Samantha Hollingworth, Senior Lecturer, School of Pharmacy, The University of Queensland, Australia |  |
| 08:45-09:45 | <b>Plenary address</b>  |  |
|             | <b>Chair:</b> Sallie Pearson, Centre for Big Data Research in Health, University of New South Wales, Australia  |  |
|             | <b>False dichotomies and health intervention research designs: Randomized trials are not always the answer - 100</b><br>Stephen Soumerai, Harvard Medical School and Harvard Pilgrim Health Care Institute, USA                                     |  |
| 09:45-10:10 | <b>Morning tea and poster viewing</b>   |  |
| 10:15-11:45 | <b>Symposium 1: PRECISION MEDICINE AND AUSTRALASIAN DATABASES IN PHARMACOEPIDEMIOLOGY STUDIES</b>   | <b>Oral presentation session 1: MANAGING CARDIOVASCULAR RISKS</b>  |
|             | <b>Moderated by:</b> Geoffrey Liu, University of Toronto, Canada<br>Samantha Hollingworth, The University of Queensland, Australia  | <b>Moderated by:</b> Judith Coombes, The University of Queensland, Australia<br>Vincent Lo Re, University of Pennsylvania, USA   |
|             | <b>Room:</b> PACE Auditorium  | <b>Room:</b> Seminar rooms 5034-5035   |
| 10:15-10:30 | <b>What is Precision Medicine? And why should it matter to pharmacoepidemiologists globally?</b><br>Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada  | <b>Comparative effectiveness and safety of low and high strength novel oral anticoagulants: A propensity-score study with sequential cohort design - 101</b><br>Emmae Ramsay, The University of South Australia, Australia                                 |
| 10:30-10:45 | <b>Integrating biological samples and associated data into large Asian databases: A Primer</b><br>Wei Zhou, Merck Center for Observational and Real World Evidence, USA   | <b>Signal evaluation of adverse drug reaction caused by non-vitamin K dependent oral anticoagulants (NOACs) in Korean adverse drug reporting system (KAERS) database - 102</b><br>Young-Jin Ko, Seoul National University College of Medicine, South Korea |
| 10:45-11:00 | <b>Pharmacogenomics: Study design and analytical approaches</b><br>Stuart MacGregor, The University of Queensland, Australia  | <b>The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation - 103</b><br>Laura Fanning, Monash University, Australia  |
| 11:00-11:15 | <b>The landscape of observational drug databases in Australia and readiness to capture biospecimen elements</b><br>Samantha Hollingworth, The University of Queensland, Australia   | <b>Aspirin reduces the risk of out-of-hospital cardiac arrest with ventricular tachycardia/ventricular fibrillation in patients with coronary artery disease - 104</b><br>Alfi Yasmina, Lambung Mangkurat University, Indonesia                            |
| 11:15-11:30 | <b>Panel discussion: Benefits and challenges of integrating precision medicine into Australasian pharmacoepidemiology research</b>  | <b>Hospital admissions due to dysglycaemia and antidiabetic medications prescriptions in England and Wales: An observational study - 105</b><br>Abdallah Naser, UCL School of Pharmacy, United Kingdom   |
| 11:30-11:45 | <b>Moderated by:</b> Sallie Pearson, Centre for Big Data Research in Health, University of New South Wales, Australia<br><b>Panellists:</b> Geoffrey Liu, Wei Zhou, Stuart MacGregor, Samantha Hollingworth   | <b>Cardiovascular safety of glucose lowering drugs in patients with type 2 diabetes mellitus and cardiovascular disease: A network meta-analysis - 106</b><br>Guangyao Li, Peking University, China  |
| 11:45-12:40 | <b>Lunch and poster discussions</b>   |  |
| 12:45-13:30 | <b>Plenary address</b>  |  |
|             | <b>Chair:</b> Debra Rowett, Drug and Therapeutics Information Service, Australia  |  |
|             | <b>Room:</b> PACE Auditorium  |  |
|             | <b>Beyond symptom control in ADHD – the contribution of pharmacoepidemiology in addressing benefit and risk - 107</b><br>Ian Chi Kei Wong, UCL School of Pharmacy, United Kingdom   |  |

|             |   |  |
|-------------|---|--|
| 13:30-15:00 | <b>Oral presentation session 2: GROWING OLDER WITH PSYCHOACTIVE MEDICINES</b>   | <b>Oral presentation session 3: METHODS AND GOOD PUBLIC POLICY</b>   |
|             | <b>Moderated by:</b> Samantha Hollingworth, The University of Queensland, Australia<br>Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada   | <b>Moderated by:</b> Byung-Joo Park, Seoul National University College of Medicine, South Korea<br>John McEwen, Therapeutic Goods Administration, Australia  |
|             | <b>Room:</b> Seminar rooms 5034-5035  | <b>Room:</b> PACE Auditorium   |
| 13:30-13:45 | <b>Doubt of association between the proton pump inhibitors and the risk of dementia: Signal detection using prescription sequence symmetry analysis - 108</b><br>Sun-Kyeong Park, Sungkyunkwan University, South Korea  | <b>The discrepancy between Mantel-Haenszel and conditional logistic estimators in a case-crossover study: An exploratory study followed by a simulation study - 114</b><br>Kiyoshi Kubota, NPO Drug Safety Research Unit, Japan                |
| 13:45-14:00 | <b>Risk of dementia in proton pump inhibitors users as compared with histamine-2 receptor antagonist: Propensity-score matched cohort study in Korea - 109</b><br>Sun-Kyeong Park, Sungkyunkwan University, South Korea   | <b>Data linkage and patients' perspective: Insights from a national survey in the United States - 115</b><br>Soko Setoguchi, Rutgers University, United States   |
| 14:00-14:15 | <b>Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies - 110</b><br>Salman Hussain, Hamdard University, India   | <b>Investigating use of administrative data sets for safety signal verification in the setting of therapeutic goods regulation in Australia - 116</b><br>Margaret Wilson, Therapeutic Goods Administration, Australia                          |
| 14:15-14:30 | <b>Incidence and risk factors of mortality among schizophrenia and antipsychotic-treated patients in Taiwan - 111</b><br>Darmendra Ramcharran, Janssen Research and Development Global Epidemiology, United States  | <b>Development of a risk proportionality framework for the selection of risk minimisation interventions in Asia: Results of a pre-Delphi panel - 117</b><br>Yola Moride, Universite de Montreal, Canada  |
| 14:30-14:45 | <b>A group based trajectory analysis of longitudinal psychotropic agents use and associated adverse outcomes in the elderly - 112</b><br>Shih-Tsung Huang, National Taiwan University, Taiwan   | <b>But what is the cost? Application of pharmacoepidemiological methods assist payers in quantifying uncertainties in cost of medicines - 118</b><br>Maxine Freeman-Robinson, The University of South Australia, Australia                     |
| 14:45-15:00 | <b>Evaluating the impact of two Pharmaceutical Benefits Scheme (PBS) restriction changes on quetiapine use: An interrupted time series analysis - 113</b><br>Jonathan Brett, Centre for Big Data Research in Health, Australia  | <b>The predictive validity for mortality of a prescription-based comorbidity index: An updated Rx-Risk index - 119</b><br>Mhairi Kerr, The University of South Australia, Australia  |
| 15:00-15:25 | <b>Afternoon tea and poster viewing</b>   |  |
| 15:30-17:00 | <b>Symposium 2: VALIDATION OF LARGE ADMINISTRATIVE DATABASES IN ASIA: METHODOLOGICAL AND PRACTICAL CHALLENGES</b>   | <b>Oral presentation session 4: ISSUES OF SAFETY AND QUALITY</b>   |
|             | <b>Room:</b> PACE Auditorium  | <b>Room:</b> Seminar rooms 5034-5035   |
|             | <b>Moderated by:</b> Kiyoshi Kubota, NPO Drug Safety Research Unit, Japan<br>Cynthia de Luise, Worldwide Safety and Regulatory, Pfizer, USA   | <b>Moderated by:</b> Christine Staatz, The University of Queensland, Australia<br>Yea-Huei Kao Yang, National Cheng Kung University, Taiwan  |
| 15:30-15:45 | <b>Validation studies of claims data in Japan – An overview and case study on the accuracy of Japanese claims data in identifying breast cancer</b><br>Izumi Sato, Kyoto University; The Keihanshin Consortium for Fostering the Next Generation of Global Leaders in Research, Japan | <b>Drug-induced anaphylaxis in the hospital setting in Beijing, China: A retrospective analysis of the Beijing Pharmacovigilance Database - 120</b><br>Xiaotong Li, Peking University Third Hospital, China                                    |
| 15:45-16:00 |   | <b>Factors associated with intravenous and repeated use of epinephrine for drug-induced anaphylaxis: A retrospective analysis of the Beijing Pharmacovigilance Database - 121</b><br>Ying Zhao, Peking University Health Science Center, China |
| 16:00-16:15 | <b>Taiwan experience and future developments</b><br>Arnold Chan, National Taiwan University, Taiwan   | <b>The association between parkinsonism and drugs possibly related with parkinsonism in Korea: A population-based case-control study - 122</b><br>Siin Kim, Pusan National University, South Korea   |
| 16:15-16:30 | <b>Validation in Hong Kong - challenges, opportunities and needs compared to other data sources</b><br>Ian C K Wong, University College London, United Kingdom; University of Hong Kong, Hong Kong  | <b>Adverse effects of <math>\beta</math>-blockers in older nursing home residents after acute myocardial infarction - 123</b><br>Andrew Zullo, Brown University School of Public Health, United States   |
| 16:30-16:45 | <b>Panel discussion: Issues and themes on conducting validation studies in Asia</b><br>Izumi Sato, Arnold Chan, Ian C K Wong and Soko Setoguchi, Rutgers University, USA  | <b>Active surveillance systems for vaccine safety: A systematic review of the surveillance models - 124</b><br>Ting Cai, Peking University, China  |
| 16:45-17:00 |   | <b>What do consumers want to know about their medicines? Consumer queries compared to medicines use? - 125</b><br>Treasure McGuire, The University of Queensland, Australia  |
| 17:00       | End of day 1  |  |

## Monday 30 October 2017 continued

|             |  |
|-------------|--|
| 17:00-18:00 | <b>Medicines Use Research Australia (MURA) Session: DUR - INFORMING AND EVALUATING POLICY</b><br><b>Room:</b> Seminar rooms 5034-5035<br>Alicia Seagrave, Drug Utilization Sub-Committee, Australian Department of Health, Australia<br>Sallie Pearson, Centre for Big Data Research in Health, University of New South Wales, Australia |
| 19:00-22:00 | <b>Conference dinner</b><br>South Bank Surf Club, 30aa Stanley Plaza, South Bank Parklands   |

## Tuesday 31 October 2017

|             |  |   |
|-------------|--|---|
| 08:30-16:30 | <b>Registration desk open</b><br>Level 5 foyer, The Pharmacy Australia Centre of Excellence (PACE)   |   |
| 08:00-09:00 | <b>Asian Pharmacoepidemiology Network (AsPEN) Session: INTRODUCTION TO ASIAN PHARMACOEPIDEMOLOGY</b><br><b>Room:</b> PACE Auditorium<br><b>AsPEN introduction and our achievements so far</b><br>Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan<br><b>Current and ongoing studies</b><br>Kenneth Mann, University of Hong Kong, Hong Kong<br><b>Challenges and future directions for AsPEN</b><br>Nicole Pratt, The University of South Australia, Australia<br><b>Interactive discussion</b> |   |
| 09:00-10:30 | <b>Oral presentation session 5: PAEDIATRIC ISSUES, PAIN AND OPIOID USE</b>   | <b>Oral Presentation session 6: HEALTHY PREGNANCIES AND NEOPLASTIC ISSUES</b>   |
|             | <b>Moderated by:</b> Adam LaCaze, The University of Queensland, Australia<br>Soko Setoguchi, Rutgers University, United States   | <b>Moderated by:</b> Genevieve Gabb, Royal Adelaide Hospital, Australia<br>Siyan Zhan, Peking University, China   |
|             | <b>Room:</b> PACE Auditorium   | <b>Room:</b> Seminar rooms 5034-5035  |
| 09:00-09:15 | <b>Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis. - 126</b><br>Kenneth Man, University of Hong Kong, Hong Kong  | <b>Exposure to teratogenic medicines before, during and after pregnancy in New South Wales, Australia - 132</b><br>Smriti Raichand, University of New South Wales, Australia  |
| 09:15-09:30 | <b>Metabolic side effects of antipsychotics in children, adolescents and young adults – an international multi-database pharmacoepidemiologic study - 127</b><br>Edward Chia-Cheng Lai, National Cheng Kung University, Taiwan   | <b>Risk of adverse perinatal outcomes associated with early pregnancy use of renin-angiotensin system blockers for the management of chronic hypertension - 133</b><br>Bilal Ahmed, Centre for Big Data Research in Health, Australia                   |
| 09:30-09:45 | <b>An ecological study of the extent and factors associated with the use of fentanyl across Australia - 128</b><br>Natasa Gisev, University of New South Wales, Australia  | <b>Safety of varenicline versus prescription nicotine patches during pregnancy: Findings from Smoking MUMS (Maternal Use of Medications and Safety) Study - 134</b><br>Duong Tran, Centre for Big Data Research in Health, Australia                    |
| 09:45-10:00 | <b>Predictors of persistent use of prescription opioid analgesics among people without cancer - 129</b><br>Samanta Lalic, Monash University, Australia   | <b>Patterns of care for long-term surviving trastuzumab-treated patients with HER2-positive metastatic breast cancer (HER2+MBC): An Australian whole-of-population cohort study - 135</b><br>Benjamin Daniels, University of New South Wales, Australia |
| 10:00-10:15 | <b>Change in utilisation of long-acting oxycodone after introduction of oxycodone/naloxone in Australia: A population-based study - 130</b><br>Andrea Schaffer, Centre for Big Data Research in Health, Australia  | <b>Incidence of comorbidities in women treated with tamoxifen or an aromatase inhibitor: An Australian population based cohort study - 136</b><br>Huah Shin Ng, The University of South Australia, Australia  |
| 10:15-10:30 | <b>Quantifying the extent that PBS/RBS claims data under-estimate opioid analgesic utilisation in Australia - 131</b><br>Natasa Gisev, University of New South Wales, Australia  | <b>Statins use and the risk of prostate cancer: A nationwide population-based cohort study - 137</b><br>Wei Ho, National Taiwan University, Taiwan  |
| 10:30-10:55 | <b>Morning tea and poster viewing</b>  |   |

|             |   |  |
|-------------|---|--|
| 11:00-12:30 | <b>Poster discussions with all presenters AND spotlight poster sessions</b>   |  |
| 11:00-11:30 | <b>Session 1: BLEEDING ISSUES AND NSAIDs</b><br><b>Moderated by:</b> Judith Coombes, The University of Queensland, Australia<br><b>Bleeding-related hospital admissions and 30-day readmissions with dabigatran versus warfarin in patients with nonvalvular atrial fibrillation - 201</b><br>Wallis CY Lau, The University of Hong Kong, Hong Kong<br><b>'Real-world' hemorrhagic rates for antithrombotics using a self-controlled case series design - 202</b><br>Prasad Nishtala, University of Otago, Taiwan<br><b>High-risk non-steroidal anti-inflammatory drug (NSAID) prescribing in primary care: Results from a developing nation - 203</b><br>Mei Fong Lim, Ministry of Health Malaysia, Malaysia<br><b>Non-steroidal anti-inflammatory drugs and risk of first hospitalization for heart failure: A population-based case-crossover study - 204</b><br>Sung-Po Huang, National Taiwan University, Taiwan   |  |
| 11:30-12:00 | <b>Session 2: CARDIOVASCULAR ISSUES AND DIABETES</b><br><b>Moderated by:</b> John McEwen, University of Canberra, Australia<br><b>Statin use and risk of new-onset diabetes in hypertensive patients: A population-based retrospective cohort study in mainland China - 206</b><br>Hailong Li, Peking University, China and Siyan Zhan, Peking University, China<br><b>Selective prescribing and estimation of risks and benefits of statins in aged care services - 207</b><br>Jenni Ilomaki, Monash University, Australia<br><b>Effects of cilostazol and renin-angiotensin-aldosterone system (RAS) blockers on the progression of renal disease in diabetic patients - 208</b><br>Sukhyang Lee, Ajou University, South Korea<br><b>Impacts of FDA safety warning and introduction of new class medications on treatment outcomes in patients with type 2 diabetes - 209</b><br>Kai-Cheng Chang, Linkou Chang Gung Memorial Hospital, Taiwan                               |  |
| 12:00-12:30 | <b>Session 3: POT-POURRI</b><br><b>Moderated by:</b> Richard Hill, Therapeutic Goods Administration, Department of Health, Australia<br><b>Comparing strategies to monitor for a potential association between teriparatide and adult osteosarcoma - 211</b><br>Kirk Midkiff, RTI Health Solutions, USA<br><b>Design considerations for developing smartphone app-based side effect monitoring systems for patients taking oral anticancer medications - 212</b><br>Eskinder Eshetu Ali, National University of Singapore, Singapore<br><b>Use of epinephrine in patients with drug-induced anaphylaxis: An analysis of the Beijing Pharmacovigilance Database - 213</b><br>Ying Zhao, Peking University, China<br><b>Sequence symmetry analysis of Pharmaceutical Benefits Scheme data for signal detection in the setting of therapeutic goods regulation in Australia - 214</b><br>Clare King, Therapeutic Goods Administration, Department of Health Australia, Australia |  |
| 12:30-13:25 | <b>Lunch and poster viewing</b>   |  |
| 13:30-15:00 | <b>Symposium 3: POST-APPROVAL SAFETY MONITORING AND ACTIVE SURVEILLANCE: EASTERN ASIA'S PERSPECTIVE</b><br><b>Moderated by:</b> Arnold Chan, National Taiwan University<br><b>Room:</b> Seminar rooms 5034-5035<br><b>Australia - history, current status, future initiatives</b><br>John McEwen, University of Canberra; Therapeutic Goods Administration, Australia<br><b>Post-approval safety surveillance in Japan: Regulation changes in 2017 and the future</b><br>Shinichi Matsuda, Chugai Pharmaceutical Co, Japan<br><b>Development of drug safety management system in Korea</b><br>Byung Joo Park, Seoul National University, Korea<br><b>Panel discussion</b><br>John McEwen, Shinichi Matsuda, Byung Joo Park, and Solomon Iyasu, Merck Research laboratories, USA; Siyan Zhan, Peking University Health Science Center, China   | <b>Symposium 4: A NATIONAL APPROACH OF PHARMACOEPIDEMIOLOGIC RESEARCH: THE CANADIAN NETWORK FOR OBSERVATIONAL DRUG EFFECT STUDIES (CNODES)</b><br><b>Moderated by:</b> David Henry, Bond University, Australia<br><b>Room:</b> PACE Auditorium<br><b>Introduction: Mission, objectives, organisation of CNODES</b><br>Adrian Levy, Dalhousie University, Canada<br><b>CNODES methods and training activities</b><br>Robert Platt, McGill University, Canada<br><b>Methods and results of key CNODES studies</b><br>Kristian Filion, McGill University, Canada<br><b>CNODES knowledge translation and dissemination activities</b><br>Adrian Levy, Dalhousie University, Canada<br><b>Conclusion/Q&amp;A</b><br>Adrian Levy, Dalhousie University, Canada |
| 15:00-15:15 | <b>Afternoon tea and poster viewing</b>   |  |
| 15:20-16:05 | <b>Plenary address</b><br><b>Chair:</b> Nicole Pratt, University of South Australia, Australia<br><b>Room:</b> PACE Auditorium<br><b>Pharmacoepidemiology in Nordic countries, a fairy tale? - 138</b><br>Jesper Hallas, President, International Society for Pharmacoepidemiology; University of Southern Denmark, Denmark   |  |
| 16:05-16:30 | <b>Closing and award ceremony</b>   |  |